Drosophila melanogaster protein phosphatase inhibitor-2: identification of a site important for PP1 inhibition  by Helps, Nicholas R. & Cohen, Patricia T.W.
Drosophila melanogaster protein phosphatase inhibitor-2:
identi¢cation of a site important for PP1 inhibition
Nicholas R. Helps*, Patricia T.W. Cohen
Medical Research Council Protein Phosphorylation Unit, Department of Biochemistry, MSI/WTB Complex, University of Dundee,
Dundee DD1 5EH, UK
Received 16 September 1999; received in revised form 5 November 1999
Edited by Avril Somlyo
Abstract A database search with human protein phosphatase
inhibitor-2 (I-2) identified a Drosophila melanogaster cDNA that
encoded a protein identical in length and sharing 39% amino acid
identity (58% similarity) with human I-2. The mRNA encoding
this protein is expressed in both sexes and throughout develop-
ment, unlike Drosophila inhibitor-t. The bacterially expressed
protein was a specific inhibitor of protein phosphatase 1 with an
IC50 of 6 1 nM, confirming that it is the Drosophila homologue
of mammalian inhibitor-2. Mutation of Phe residues conserved in
I-2 from lower and higher eukaryotes showed that Phe-33 is
important for inhibition of PP1c.
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1. Introduction
Protein phosphatase 1 (PP1) is a major protein serine/threo-
nine phosphatase involved in the regulation of numerous
processes such as cell division, metabolism, RNA splicing,
protein synthesis and muscle contraction (reviewed in [1,2]).
The PP1 catalytic subunit (PP1c) is controlled in vivo through
its interaction with a diverse group of targetting subunits,
which serve to tether PP1c to a particular subcellular location
and/or modulate its catalytic activity. In skeletal muscle PP1c
is targetted to glycogen and the sarcoplasmic reticulum by a
126 kDa targetting subunit known as GM [3,4]. This binds to
glycogen with high a⁄nity and enhances dephosphorylation
of glycogen-bound substrates such as glycogen synthase and
phosphorylase. A distinct 33 kDa glycogen targetting subunit
(GL) exists in the liver [5]. In smooth muscle PP1c is targetted
to myo¢brils by a complex consisting of a 110 kDa and a 21
kDa subunit [6]. This heterotrimer, known as PP1M, has en-
hanced activity towards smooth muscle myosin compared
with PP1c. Striated muscle also contains a PP1M complex
that targets PP1c towards skeletal muscle myosin [7]. Many
other PP1c targetting subunits have been identi¢ed recently,
including NIPP1 [8] and PNUTS/p99 [9,10], which target
PP1c to RNA and the p53 binding protein 53BP2 [11].
In addition to a wide variety of regulatory subunits, PP1
binds to a number of small cytosolic inhibitor proteins. Clas-
sical inhibitors include inhibitor-1 (I-1) and its isoform
DARPP-32 that are thought to enhance the e¡ects of cyclic
AMP signalling through protein kinase A [1,2] and the struc-
turally distinct inhibitor-2 (I-2), which may promote the cor-
rect folding of newly synthesised PP1 [12]. Recently several
novel PP1 inhibitor proteins have been isolated, including
CPI17, a mammalian smooth muscle-speci¢c PP1 inhibitor
[13], the human HCG V gene product (inhibitor-3) [14] and
inhibitor-t, a testis-speci¢c PP1 inhibitor from Drosophila me-
lanogaster that has 41% sequence similarity to mammalian I-2
[15]. Homologues of I-2 are known from human, rabbit and
rat species [16,17] and Glc8p is the likely homologue of I-2
from Saccharomyces cerevisiae [18]. Studies performed some
years ago showed that an activity possessing the character-
istics of I-2 could be identi¢ed in D. melanogaster [19]. Here
we have characterised a protein that possesses this activity in
D. melanogaster (Dm) and shown that a conserved Phe resi-
due in the N-terminal region of Dm I-2 is essential for potent
inhibition of PP1c.
2. Materials and methods
2.1. Identi¢cation and sequence analysis of the cDNA encoding
D. melanogaster I-2
The National Center for Biotechnology Information (NCBI) ex-
pressed sequence tag database (dbEST) was searched with the human
I-2 protein sequence using the TBLASTN algorithm [20]. Five cDNA
sequences from two di¡erent D. melanogaster libraries were identi¢ed
that encoded portions of a polypeptide with signi¢cant sequence iden-
tity to human I-2. One of these (clone ID GH10368) was obtained
from the Berkeley Drosophila Genome Project (DBGP) via Research
Genetics, Inc. (Huntsville, AL, USA) and digested with EcoRI and
XhoI to release the cDNA insert. A complex pattern of DNA frag-
ments with a total length of approximately 4.5 kb (not shown) was
obtained. The cDNA encoding I-2 was analysed by primer-walking on
the presumed coding strand. Sequencing was performed by Dr A. Hill
(MSI/WTB complex central DNA sequencing service, University of
Dundee) on an Applied Biosystems model 373AStretch automated
DNA sequencer using BigDye terminator chemistry.
2.2. General methods and reagents
Oligonucleotides were synthesised by Miss K. Maxwell (University
of Dundee) on an Applied Biosystems model 394 DNA synthesiser.
Synthetic peptides were synthesised on an Applied Biosystems 430A
peptide synthesiser and puri¢ed by Mr F.B. Caudwell. Total RNA
was puri¢ed from D. melanogaster (Oregon R strain) and subjected to
formaldehyde gel electrophoresis and Northern blotting as described
in [21] using ‘Rapid-hyb’ bu¡er (Amersham Life Science, Bucks, UK).
2.3. Bacterial expression and puri¢cation of D. melanogaster I-2
The 615 nt open reading frame (ORF) encoding the entire inhibitor-
2 protein (205 amino acids) was ampli¢ed in a polymerase chain
reaction (PCR) using the 1503 nt Dm I-2 cDNA as a template. The
oligonucleotide primers GCCCATATGCAGAACAATCCCAGCC
and GCTCTAGACTAGTTATTCGATGGCTCCAG incorporate
NdeI and XbaI sites (underlined) at the initiating and terminating
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codons (italicised) respectively. The PCR product was cloned into the
plasmid pCR2.1 using the TOPO cloning system (Invitrogen) and the
sequence of the insert con¢rmed. Due to technical di⁄culties encoun-
tered when we attempted to clone the ORF into the pT7-7 vector [22]
using the NdeI and XbaI sites, we instead utilised a HindIII site in the
pCR2.1 plasmid multiple cloning site to clone the Dm I-2 ORF into
pT7-7 on NdeI and HindIII sites. Following sequence con¢rmation,
the construct was transformed into the Escherichia coli strain
BL21(DE3)pLysS and transformants selected on LB plates containing
ampicillin (50 Wg/ml) and chloramphenicol (25 Wg/ml). Expression and
puri¢cation of Dm I-2 was then performed as for human I-2 [17]. The
peak I-2 fraction from Mono-Q chromatography, which eluted at
230 mM NaCl, was collected and stored at 370‡C.
2.4. Mutagenesis of the D. melanogaster I-2 cDNA
F33 within the Dm I-2 protein was changed to A33 using the
complementary oligonucleotides GCAAAAGTGCCAAGGCCGAT-
GAGCTGAACG and CGTTCAGCTCATCGGCCTTGGCACTTT-
TGC (mutated codon underlined) in a QuikChange (Stratagene) mu-
tagenesis reaction on the pT7-7 expression construct. F119 was
mutated similarly using the complementary oligonucleotides
CGGCGCGAAGCTGAGCGACGCC and GCGTCGCTCAGCTT-
CGCGCCGC (mutated codon underlined). The mutations were con-
¢rmed by sequence analysis.
2.5. Protein phosphatase and inhibitor assays
Phosphatase assays were performed in the presence of 0.5 mM
Mn2 (PP1-87B) or in the absence of divalent cations (PP2A1) using
32P-labeled rabbit skeletal muscle glycogen phosphorylase [23]. One
unit of phosphatase activity is that amount of enzyme that catalyses
the release of 1 Wmol [32P]phosphate/min from phosphorylase a. I-2
was assayed as in [24]. One unit of I-2 is that amount that inhibits the
dephosphorylation of 0.01 mU of PP1 by 50% in the standard 30 Wl
assay.
3. Results
3.1. Identi¢cation of the cDNA encoding D. melanogaster
inhibitor-2
Sequence analysis of a cDNA from the NCBI EST database
identi¢ed an ORF encoding a polypeptide of 205 amino acids
with regions of high sequence identity to human I-2 (Fig. 1).
The sequence at the presumed initiating codon (CAGGATG)
conforms reasonably well to the consensus for D. melanogas-
ter translation initiation of (C/A)AA(A/C)ATG [25]. Although
there is one other ATG codon preceding the presumed initiat-
ing codon, this is followed by two stop codons. The 1503 bp
cDNA contains 249 bp of 5P untranslated region (UTR) and
636 bp of 3P UTR and has been deposited in the GenEMBL
database under the accession number AJ133246. 1503 bp is
much smaller than the size of the insert DNA (4.5 kb) re-
vealed by restriction digest analysis of the EST clone. This
discrepancy is explained by the presence of a second cDNA
insert cloned into the vector downstream of and in the oppo-
site orientation to the I-2 cDNA. The identity of this cDNA
has not been investigated.
3.2. Comparison of the predicted D. melanogaster I-2 with
other I-2 sequences
Fig. 1 shows a comparison of the predicted Dm I-2 protein
with human I-2, the S. cerevisiae Glc8 protein and a putative
Caenorhabditis elegans I-2 protein. The C. elegans I-2 protein
sequence (Wormpep ID: Y32H12A_69.A) was identi¢ed by a
search of the C. elegans Wormpep database (The Sanger
Centre, Hinxton Hall, Cambridge, UK) using the human I-2
Fig. 1. Comparison of the predicted D. melanogaster inhibitor-2 protein (DmI2) with human inhibitor-2 (HsI2), the putative C. elegans inhibi-
tor-2 protein (CeI2) and the S. cerevisiae GLC8 protein. Numbering of the amino acids is from the residue following the initiating Met, which
is cleaved from the mature protein. The ¢ve conserved regions of sequence (I^V) are indicated by brackets and threonines 59 of DmI2, 72 of
HsI2, 79 of CeI2 and 117 of GLC8 are indicated (*). The comparison was created using the program PILEUP (Genetic Computer Group,
Madison, WI, USA) followed by manual optimisation of the alignment and shading was performed using the program BOXSHADE (v3.21,
K. Hofmann and M. Baron).
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protein sequence. Dm I-2 has 39% identity (58% similarity if
conservative substitutions are included) to human I-2 and
41% identity (61% similarity) to the predicted C. elegans I-2.
These ¢gures are comparable to the 37% identity (53% sim-
ilarity) between human I-2 and the predicted C. elegans I-2
protein. As expected, lower levels of identity are seen between
all of these I-2 proteins and Glc8p.
Fig. 1 reveals highly conserved sections of sequence among
the proteins. Residues between amino acids 52 and 61 of Dm
I-2 (conserved region III) are almost totally conserved be-
tween all four proteins. Four other regions of conservation
(conserved regions I, II, IV and V; Fig. 1) are also apparent.
Regions IV and V consist largely of basic and acidic residues
respectively. It is also of interest that, despite D. melanogaster,
C. elegans and human I-2 all being very similar sizes (in fact
Dm I-2 is identical in length to human I-2; 205 amino acids),
the optimal alignment leads to substantial insertions and de-
letions in certain areas of the proteins. These are presumably
regions of the proteins not essential for a common function.
3.3. Expression of the Dm I-2 mRNA during D. melanogaster
development
Fig. 2A shows that an mRNA species of 1.6 kb can be
detected at all stages of development. This size of mRNA is
consistent with the length of Dm I-2 cDNA (1.5 kb) isolated.
Reprobing the blot with the cDNA for PP1-87B (Fig. 2B),
which is reasonably evenly expressed during D. melanogaster
development [26], demonstrates that the level of the Dm I-2
mRNA is also fairly constant. The one possible exception is in
0^4 h embryos (Fig. 2A, lane 1) where the Dm I-2 mRNA
appears more abundant than at other stages of development.
The two PP1-87B mRNAs also appear more abundant in
these early embryos than at later stages of development, as
has been observed previously [15]. Since PP1-87B represents
the most abundant PP1 isoform in D. melanogaster [27], it is
likely that the level of I-2 mirrors that of PP1-87B in order
that PP1 is folded and/or it activity controlled e⁄ciently.
3.4. Puri¢cation and assay of D. melanogaster I-2 expressed in
E. coli
Expression of the Dm I-2 cDNA in E. coli produced a 30
kDa band visible in the initial extract (Fig. 3, lane 1) that,
after heating at 100‡C, was found in the soluble fraction (Fig.
3, lane 2). Chromatography on Mono Q resulted in puri¢ca-
tion of the 30 kDa I-2 protein (Fig. 3, lane 4), which was
tested on D. melanogaster PP1-87B [15] using 32P-labeled gly-
cogen phosphorylase as substrate. Fig. 4A shows that Dm I-2
inhibits PP1-87B with a Ki of less than 1 nM in the standard
assay. This is identical to the inhibition observed with human
I-2 (data not shown). As expected for an I-2 protein, the
polypeptide did not signi¢cantly inhibit the phosphatase ac-
tivity of PP2A1 (Fig. 4A). We have previously shown that
mutagenesis of a conserved Phe within the C-terminus of
the D. melanogaster inhibitor-t protein, which is related to
I-2, disrupts the ability of this protein to inhibit PP1 [15].
To determine whether this was also the case for Dm I-2, we
mutated Phe-119 to Ala and puri¢ed the mutant protein to
homogeneity as for the wild type protein. When this protein
was added to PP1-87B in a standard assay, it inhibited PP1-
87B phosphatase activity as e¡ectively as wild-type Dm I-2
(Fig. 4A).
3.5. Identi¢cation of a site on D. melanogaster I-2 that
interacts with PP1-87B
Previous studies using short synthetic peptides derived from
the GM regulatory subunit of PP1 have identi¢ed a hydro-
phobic groove on the surface of human PP1c that is respon-
sible for binding many PP1 regulatory subunits [28]. In order
to determine whether PP1-87B also binds D. melanogaster I-2
Fig. 2. Expression of I-2 mRNA during D. melanogaster develop-
ment. 25 Wg of total RNA from the developmental stages shown
was separated on a denaturing 1% agarose gel and transferred to
nylon membrane. The membrane was probed with a 600 bp 32P-ra-
diolabelled NdeI-XbaI fragment from the plasmid pCR2.1 contain-
ing the entire open reading frame for Dm I-2 (A). The membrane
was subsequently probed with a 32P-radiolabelled fragment of
D. melanogaster protein phosphatase 1-87B [26] to control for load-
ing (B). Lanes are: E1, 0^4 h embryos; E2, 4^24 h embryos;
L, third instar larvae; P, pupae; F, adult female; M, adult male.
Sizes are in kb. Transcripts are indicated (arrows).
Fig. 3. Puri¢cation of D. melanogaster I-2 protein expressed in E.
coli. Protein samples from the stages of puri¢cation shown were
separated on a 10% SDS-PAGE and stained with Coomassie bril-
liant blue R250 to visualise the proteins. Lanes are: M, markers; 1,
10 Wg of whole cell soluble extract from E. coli expressing I-2; 2,
supernatant from 10 Wg of E. coli extract heated to 100‡C and cen-
trifuged; 3, 5 Wg of £ow through from Mono Q column; 4, 2 Wg of
Dm I-2 eluted from Mono Q; 5, 2 Wg of human I-2. Marker sizes
are in kDa.
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through this groove, peptides that disrupt PP1c^regulatory
subunit interactions were utilised. These peptides e¡ectively
relieved the inhibition of PP1c phosphatase activity caused
by I-2 in standard phosphatase assays (Fig. 4B). Control pep-
tides, containing FCA or WCA mutations in the -(K/R)(V/I)-
X(F/W)- motif were ine¡ective at relieving I-2 inhibition (Fig.
4B). In order to ascertain whether I-2 might contain a se-
quence similar to the -(K/R)(V/I)X(F/W)- motif, we searched
the aligned I-2 sequences from mammals and lower eukar-
yotes for conserved F/W residues (Fig. 1). Only two such sites
exist, which are F33 and F119 in Dm I-2. Mutation of F33A
increased the IC50 of Dm I-2 for PP1 approximately 30-fold
(from 0.6 nM to 17 nM), while mutation of F119A did not
a¡ect the inhibition of Dm I-2 for PP1 (Fig. 4A). In the
phosphatase standard assay, wild type Dm I-2 at 10 nM
gave 90% inhibition of PP1c, while Dm I-2(F33A) at 10 nM
showed only 45% inhibition of PP1c (Fig. 4C). The concen-
trations of wild type Dm I-2 and Dm I-2(F33A) were quanti-
tated both by Bradford assay and by Coomassie staining after
gel electrophoresis. The 53BP2 peptide relieved the residual
inhibition of PP1c by the Dm I-2(F33A) mutant at a 10-
fold lower peptide concentration (100 nM) than that (1 WM)
required to relieve the inhibition of PP1c by wild type I-2 (Fig.
4C).
4. Discussion
Several lines of evidence demonstrate that the D. mela-
nogaster sequence we present here is the bona ¢de homologue
of mammalian I-2. The mRNA is expressed at all stages of
D. melanogaster development and is present at equal levels in
adults of both sexes, as observed for the mRNA encoding the
major isoform of D. melanogaster PP1. In contrast, the
D. melanogaster PP1 inhibitor protein we recently identi¢ed
(termed I-t) is only expressed in testis [15]. Dm I-2 shares
much higher sequence identity with human I-2 (39%) than
I-t exhibits (21%) and both inhibitor proteins possess the con-
served threonine residue (Thr-59 in Dm I-2) necessary for
activation of an inactive complex of PP1c and I-2 (termed
PP1I) by glycogen synthase kinase-3 (GSK-3) [1,2]. However,
a residue corresponding to Ser-86 of human I-2 which, when
phosphorylated by casein kinase II, increases phosphorylation
of Thr72 by GSK-3 [29], does not appear to be present within
the D. melanogaster inhibitor proteins. The bacterially ex-
pressed Dm I-2 speci¢cally inhibits the activity of PP1c at
nanomolar concentrations in standard phosphatase assays,
while I-t is a much less potent inhibitor of PP1. Both inhib-
itors share additional features common to inhibitor proteins
from other species, including thermostability and aberrant
migration on SDS-PAGE.
Comparison of the human and Dm I-2 sequences with
S. cerevisiae Glc8p and with a protein likely to represent
C. elegans I-2 (Fig. 1) reveals some interesting features. The
amino-terminal regions of the proteins are highly divergent,
but encompass a short section (conserved region I) containing
the motif (G/S)ILK. Deletion studies have identi¢ed the ami-
no-terminus of I-2 as essential for PP1c inhibition [30,31] and
mutagenesis studies have elucidated a number of key residues
for inhibitor-2 function, including some of those present with-
in the (G/S)ILK motif [30]. We have shown that residues
within the amino-terminus of I-2 contribute signi¢cantly to
the inhibitory capacity of I-2 through generation of a fusion
protein between human I-2 and the D. melanogaster I-t. This
Fig. 4. E¡ect of I-2 proteins on the phosphorylase phosphatase ac-
tivity of PP1-87B and PP2A1. Phosphatase activity is given as a per-
centage of the maximum obtained in the absence of any inhibitors.
A: The PP1-87B catalytic subunit was incubated with wild type (E),
F119A (7), F33A (a) Dm I-2. PP2A1 was incubated with wild
type Dm I-2 (O). B: Relief of Dm I-2 inhibition of PP1-87B by
synthetic peptides. PP1 activity was measured in the presence of
10 nM Dm I-2 and increasing amounts of peptides. F, 53BP2 pep-
tide (GQVSLPPGKRTNLRKTGSERIAMGMRVKFNPLALLLD-
SC); R, NIPP1 peptide (KRKNSRVTFSED); b, p99 peptide (GR-
KRKSVTWPEEGKLR); E, 53BP2 control peptide (GQVSLP-
PGKRTNLRKTGSERIAMGMRVKANPLALLLDSC); O, NIPP1
control peptide (REKPQTLPSAVKGD); a, p99 control peptide
(GRKRKSVTAPEEGKLR). The consensus PP1 binding site is
underlined in the peptide sequences. In all assays the maximal
release of 32P from phosphorylase a in the absence of inhibitors
was 10%. C: E¡ect of peptides on the inhibition of PP1-87B by
wild type (E,F) and F33A (a,b) Dm I-2. Closed symbols, 53BP2
peptide (GQVSLPPGKRTNLRKTGSERIAMGMRVKFNPLAL-
LLDSC); open symbols, 53BP2 control peptide (GQVSLPPG-
KRTNLRKTGSERIAMGMRVKANPLALLLDSC).
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chimaeric protein, which contains conserved region I of hu-
man I-2, has signi¢cantly greater inhibitory activity than the
native I-t protein that lacks such a motif [15].
Conserved region III contains the Thr residue that is phos-
phorylated by GSK-3, resulting in activation of the inactive
PP1I complex [32]. Conserved regions IV and V are also im-
portant for I-2 function. We have previously shown that mu-
tation of the Phe residue in conserved region IV of a fusion
between human I-2 and D. melanogaster I-t results in a dra-
matic reduction in its inhibitory capability [15]. This is not the
case for human I-2 [30] and Dm I-2, possibly because con-
served region IV of I-2 makes more extensive contacts with
PP1c than the corresponding region of I-t. Alternatively, the
Phe to Ala mutation may convert I-2/I-t chimera (but not I-2)
into a conformation that is unable to bind PP1 (see below).
The two clusters of basic amino acids in this region that are
required for nuclear accumulation [33] are conserved in
D. melanogaster I-2 (amino acids 115^117 and 121^123). Pre-
vious deletion studies have shown that the area of I-2 con-
taining conserved region V is important for GSK-3 activation
of PP1I [31], although the mechanism is not known.
To investigate further the interaction between PP1c and I-2,
we utilised synthetic peptides from three PP1-interacting pro-
teins. These peptides, which contain the conserved PP1 inter-
action motifs -(K/R)(V/I)XF- or -(K/R)X(V/I)XW-, were ef-
fective in relieving some or all of Dm I-2 inhibition of PP1-
87B. This parallels previous results with mammalian PP1-in-
teracting proteins such as GM and M110 [28,34], p99 [10] and
53BP2 (Helps and Cohen, unpublished) with human PP1c.
Recent studies also showed that a 20 residue peptide from
NIPP-1 and a 40 residue peptide from M110 containing the
sequence -RVXF- relieved the inhibition of human PP1c by I-
2 [35,30]. We have shown here that despite the fact that Dm I-
2 is only 39% identical to mammalian I-2, a site of I-2 inter-
action on PP1c, essential for inhibition of phosphatase activ-
ity, is clearly conserved. A peptide as small as 12 amino acids
could e¡ect this relief of inhibition. Since mutation of F or W
within the motifs abrogated the e¡ect of the peptides, we
analysed the consequence of mutating F/W sites within Dm
I-2 that were conserved from mammals to lower eukaryotes.
Mutation of F33A in conserved region II increased the IC50 of
Dm I-2 for PP1c approximately 30-fold, indicating that this
region probably binds to PP1c. Since the sequence of Dm I-2
in this section is -RKSAKF-, and homologous sequences in
other eukaryotic I-2 proteins also resemble the PP1c binding
motif, it is possible that conserved region II may bind to the
hydrophobic groove of PP1. The fact that the 53BP2 peptide
relieved the residual inhibition of the Dm I-2(F33A) at lower
concentrations than necessary to relieve the inhibition by wild
type I-2, supports this hypothesis. However, a conformational
change cannot be completely ruled out. Although the precise
mechanism has yet to be established, alignment of I-2 sequen-
ces from lower eukaryotes with mammalian I-2 has allowed a
conserved region that is important for inhibition of PP1c to be
identi¢ed.
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